Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.060x

Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.34 Million ≈ $6.49 Million USD) by net assets (CN¥735.65 Million ≈ $107.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 605199 market cap overview for the company's overall valuation and market capitalisation.

Hainan Huluwa Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency. Explore Hainan Huluwa Pharmaceutical Group Co Lt earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Lifezone Metals Limited NYSE:LZM	-0.117x
Borosil Limited NSE:BOROLTD	0.059x
Jiangsu Jinling Sports Equipment Co Ltd SHE:300651	0.054x
Waskita Karya Persero Tbk JK:WSKT	0.035x
Regal Asian Investments Ltd AU:RG8	N/A
Companhia Energética do Ceará - Coelce SA:COCE3	-0.085x
DiaMedica Therapeutics Inc NASDAQ:DMAC	-0.192x
Zhejiang Tuna Environmental Science & Technology Co Ltd SHG:603177	0.068x

Annual Cash Flow Conversion Efficiency for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. View Hainan Huluwa Pharmaceutical Group Co Lt share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥458.02 Million ≈ $67.02 Million	CN¥136.85 Million ≈ $20.03 Million	0.299x	+248.94%
2024-12-31	CN¥743.28 Million ≈ $108.77 Million	CN¥-149.12 Million ≈ $-21.82 Million	-0.201x	-923.26%
2023-12-31	CN¥1.16 Billion ≈ $169.65 Million	CN¥28.25 Million ≈ $4.13 Million	0.024x	-89.64%
2022-12-31	CN¥1.02 Billion ≈ $148.57 Million	CN¥238.71 Million ≈ $34.93 Million	0.235x	+113.48%
2021-12-31	CN¥930.52 Million ≈ $136.16 Million	CN¥102.48 Million ≈ $15.00 Million	0.110x	+2958.79%
2020-12-31	CN¥916.48 Million ≈ $134.11 Million	CN¥3.30 Million ≈ $482.88K	0.004x	-98.40%
2019-12-31	CN¥643.94 Million ≈ $94.23 Million	CN¥144.51 Million ≈ $21.15 Million	0.224x	+326.73%
2018-12-31	CN¥604.61 Million ≈ $88.47 Million	CN¥31.80 Million ≈ $4.65 Million	0.053x	-79.46%
2017-12-31	CN¥351.38 Million ≈ $51.42 Million	CN¥89.96 Million ≈ $13.16 Million	0.256x	-49.28%
2016-12-31	CN¥128.69 Million ≈ $18.83 Million	CN¥64.96 Million ≈ $9.51 Million	0.505x	--

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic

Market Cap

$340.75 Million

CN¥2.33 Billion CNY

Market Cap Rank

#14377 Global

#4323 in China

Share Price

CN¥5.82

Change (1 day)

-0.68%

52-Week Range

CN¥5.19 - CN¥10.20

All Time High

CN¥48.21